Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy

Miller, R. F.; Allen, E.; Copas, A.; Singer, M.; Edwards, S. G.
August 2006
Thorax;Aug2006, Vol. 61 Issue 8, p716
Academic Journal
journal article
Background: Despite a decline in incidence of Pneumocystis jirovecii pneumonia (PCP), severe PCP continues to be a common cause of admission to the intensive care unit (ICU) where mortality remains high. A study was undertaken to examine the outcome from intensive care for patients with PCP and to identify prognostic factors.Methods: A retrospective cohort study was conducted of HIV infected adults admitted to a university affiliated hospital ICU between November 1990 and October 2005. Case note review collected information on demographic variables, use of prophylaxis and highly active antiretroviral therapy (HAART), and hospital course. The main outcome was 1 month mortality, either on the ICU or in hospital.Results: Fifty nine patients were admitted to the ICU on 60 occasions. Thirty four patients (57%) required mechanical ventilation. Overall mortality was 53%. No patient received HAART before or during ICU admission. Multivariate analysis showed that the factors associated with mortality were the year of diagnosis (before mid 1996 (mortality 71%) compared with later (mortality 34%; p = 0.008)), age (p = 0.016), and the need for mechanical ventilation and/or development of pneumothorax (p = 0.031). Mortality was not associated with sex, ethnicity, prior receipt of sulpha prophylaxis, haemoglobin, serum albumin, CD4 count, PaO2, A-aO2 gradient, co-pathology in bronchoscopic lavage fluid, medical co-morbidity, APACHE II score, or duration of mechanical ventilation.Conclusions: Observed improved outcomes from severe PCP for patients admitted to the ICU occurred in the absence of intervention with HAART and probably reflect general improvements in ICU management of respiratory failure and ARDS rather than improvements in the management of PCP.


Related Articles

  • Pneumocystis jirovecii pneumonia prophylaxis for HIV-exposed neonates. Bennett, Nicholas J. // Research & Reports in Neonatology;2014, Vol. 4, p71 

    Pneumocystis pneumonia (PCP) is a common, usually fatal opportunistic infection of HIV-infected infants. This review summarizes the current knowledge and recommended practices regarding PCP prophylaxis in HIV-exposed infants. The incidence of PCP has dropped dramatically in areas of the world...

  • Lung fibrosis in deceased HIV-infected patients with Pneumocystis pneumonia. Shaddock, E. J.; Richards, G. A.; Murray, J. // Southern African Journal of HIV Medicine;Jun2012, Vol. 13 Issue 2, p64 

    Background. Pneumocystis pneumonia (PcP) is one of the most common opportunistic infections found in patients with HIV. The prognosis if ventilation is required is poor, with mortality of 36 - 80%. Although more recent studies have shown improved survival, our experience has been that close to...

  • Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection. Asai, Nobuhiro; Motojima, Shinji; Ohkuni, Yoshihiro; Matsunuma, Ryo; Nakashima, Kei; Iwasaki, Takuya; Nakashita, Tamao; Otsuka, Yoshihito; Kaneko, Norihiro // Journal of Infection & Chemotherapy;Dec2012, Vol. 18 Issue 6, p898 

    The mortality of Pneumocystis pneumonia (PCP) patients without human immunodeficiency virus (HIV) infection ranges from 0 to 70 %, whereas that of HIV-infected PCP patients ranges from 10 to 20 %. The reasons for these differences are not known. We retrospectively analyzed factors contributing...

  • Clinical features of AIDS in the Edinburgh City Hospital cohort. Brettle, Raymond P.; Foreman, Angus; Povey, Sarah; Brettle, R P; Foreman, A; Povey, S // International Journal of STD & AIDS;May1996, Vol. 7 Issue 3, p190 

    In order to describe the clinical features of AIDS, particularly injection drug use (IDU) related AIDS in patients attending the Regional Infectious Diseases Unit in Edinburgh a prospective review of the 680 HIV-positive patients, 30% of whom were women and 68% were infected via IDU was...

  • Evaluation of Toluidine Blue O Staining for the Diagnosis of Pneumocystis jiroveci in Expectorated Sputum Sample and Bronchoalveolar Lavage from HIV-infected Patients in a Tertiary Care Referral Center in Ethiopia. Aderaye, G.; Woldeamanuel, Y.; Asrat, D.; Lebbad, M.; Beser, J.; Worku, A.; Fernandez, V.; Lindquist, L. // Infection;Jun2008, Vol. 36 Issue 3, p237 

    Pneumocystis pneumonia (PCP) is becoming increasingly recognized in sub-Saharan Africa. The currently recommended diagnostic methods using induced sputum (IS) and bronchoalveolar lavage (BAL) are neither technically feasible nor affordable for a wider clinical use in developing countries....

  • Retrospective review of Pneumocystis jirovecii pneumonia over two decades. Travis, J.; Hart, E.; Helm, J.; Duncan, T.; Vilar, J. // International Journal of STD & AIDS;Mar2009, Vol. 20 Issue 3, p200 

    The aim of the study was to compare a retrospective case note review of all cases of Pneumocystis carinii (now Pneumocystis jirovecii) pneumonia (PJP) over the period 1997-2004 at North Manchester General Hospital with a previous audit covering the years 1986-1995. During 1986-1995, 777 patients...

  • Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. M W Fei // Thorax;Dec2009, Vol. 64 Issue 12, p1070 

    BACKGROUND: Although the use of antiretroviral therapy has led to dramatic declines in AIDS-associated mortality, Pneumocystis pneumonia (PCP) remains a leading cause of death in HIV-infected patients. OBJECTIVES: To measure mortality, identify predictors of mortality at time of illness...

  • Pneumocystis pneumonia--Los Angeles.  // MMWR: Morbidity & Mortality Weekly Report;8/30/1996, Vol. 45 Issue 34, p730 

    Reports on Pneumocystis pneumonia cases in Los Angeles, California, from October 1980 to May 1981. Patient profiles; Complications; Statistics.

  • HIV+ patients still need PCP prophylaxis.  // AIDS Alert;Jul2007, Vol. 22 Issue 7, p80 

    The article reports that prophylaxis against pneumocystic carinii pneumonia (PCP) remains the single most cost-effective intervention in HIV+ patients at risk.


Read the Article


Sign out of this library

Other Topics